This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Tuberculosis	*Mycobacterium tuberculosis* probable ATP-dependent protease ATP-binding subunit ClpC1 (ClpC1)	*In vitro* studies identified ClpC1 as the target of antituberculosis compound cyclomarin A (CymA), which could guide the design of new ClpC1 inhibitors to treat tuberculosis. CymA has activity against both replicating and nonreplicating tuberculosis, but the 848-amino-acid protein has poor pharmacokinetics. Cocrystallization of CymA in complex with ClpC1 showed that the compound bound the N-terminal domain of ClpC1. Next steps include designing ClpC1 inhibitors with improved therapeutic properties. *SciBX* 6(39); doi:10.1038/scibx.2013.1100 Published online Oct. 10, 2013	Findings unpatented; licensing status not applicable	Vasudevan, D. *et al. J. Biol. Chem.*; published online Sept. 10, 2013; doi:10.1074/jbc.M113.493767 **Contact:** Christian G. Noble, Novartis Institute for Tropical Diseases, Chromos, Singapore e-mail: christian.noble@novartis.com